NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $679,000 | +4.6% | 37,800 | 0.0% | 0.02% | +9.1% |
| Q2 2021 | $649,000 | +3.3% | 37,800 | +20.4% | 0.02% | -12.0% |
| Q1 2021 | $628,000 | +17.6% | 31,400 | 0.0% | 0.02% | +8.7% |
| Q4 2020 | $534,000 | -12.0% | 31,400 | -14.2% | 0.02% | -20.7% |
| Q3 2020 | $607,000 | -37.4% | 36,600 | -12.6% | 0.03% | -37.0% |
| Q2 2020 | $970,000 | +29.7% | 41,900 | 0.0% | 0.05% | +2.2% |
| Q1 2020 | $748,000 | +14.7% | 41,900 | +38.7% | 0.04% | +66.7% |
| Q4 2019 | $652,000 | +167.2% | 30,200 | +125.4% | 0.03% | +145.5% |
| Q3 2019 | $244,000 | -52.1% | 13,400 | -6.3% | 0.01% | -50.0% |
| Q2 2019 | $509,000 | +5.2% | 14,300 | -0.7% | 0.02% | +4.8% |
| Q1 2019 | $484,000 | +2.3% | 14,400 | 0.0% | 0.02% | -8.7% |
| Q4 2018 | $473,000 | -46.1% | 14,400 | 0.0% | 0.02% | -30.3% |
| Q3 2018 | $878,000 | +21.4% | 14,400 | -2.7% | 0.03% | +17.9% |
| Q2 2018 | $723,000 | -55.8% | 14,800 | -3.9% | 0.03% | -54.8% |
| Q1 2018 | $1,636,000 | – | 15,400 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |